Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2017

View Archived Issues

EMA grants orphan drug designation for DCC-2618 as treatment of gastrointestinal stromal tumors

MLR-1019 ameliorates dyskinesia and neuron bursting in Parkinsonian rats

FDA accepts IND for CTLA-4 Probody therapeutic from BMS and CytomX

Axsome Therapeutics announces new product candidate for treatment of migraine

Vedanta in new and expanded collaborations to support microbiome work in cancer immunotherapy

Nippon Chemiphar completes phase I trial of NC-2500 and preclinical studies with NC-2700

Idera Pharmaceuticals' IMO-2125 awarded FDA fast track designation

FDA gives orphan drug designation to Amphivena Therapeutics' AMV-564

Melinta Therapeutics to acquire infectious disease business from The Medicines Company

Aptinyx tests PTSD candidate NYX-783 in animal models

Zogenix begins phase III study of ZX-008 in Lennox-Gastaut syndrome

Researchers develop mouse model of coronary collateral vessel growth

Peptide anti-PCSK9 vaccine shows promise for treating dyslipidemia

EMA gives orphan drug designation to ProQR Therapeutics' QR-313

HanAll initiates phase II trial of HL-036 to treat signs and symptoms of dry eye

ID Pharma submits CTN in Japan for DiscGenics' IDCT-001 clinical trial

Cambridge Enterprise, Sydney Children's Hospitals Network design viral vectors encoding factor I

Idorsia Pharmaceuticals patents novel antibacterials

Lilly identifies novel beta-secretase 1 inhibitors

Researchers present SUVN-1603054, a novel antipsychotic for treating schizophrenia

Novel soluble guanylate cyclase activators discovered at Merck & Co.

Istituto Europeo di Oncologia Srl synthesizes new lysine-specific demethylase 4C inhiibitors

First pediatric patient dosed in phase I/II study of AEB-1102 in arginase 1 deficiency

Regeneron and Decibel collaborate to develop therapeutics for hearing loss

Pharnext gives update on phase III PLEO-CMT study

Sanofi updates information on Dengvaxia

TherapeuticsMD resubmits NDA for TX-004-HR for dyspareunia

ViiV initiates phase III study of long-acting cabotegravir for prevention of HIV infection in women

AstraZeneca studies AZD-5718 in patients with coronary artery disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...